Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6029
Source ID: NCT02503943
Associated Drug: "Liraglutide" And "Mitiglinide"
Title: Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes
Acronym:
Status: UNKNOWN
Study Results: NO
Results:
Conditions: Type 2 Diabetes|Overweight|Obesity|Masked Hypertension
Interventions: DRUG: "Liraglutide" and "Mitiglinide"|DRUG: "Metformin" and "Mitiglinide"|DRUG: "Mitiglinide"
Outcome Measures: Primary: Blood Pressure change, Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks|Lipid profile (triglyceride, total cholesterol, LDL-c; HDL-c; mmol/L) change, Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks | Secondary: 24-hours mean blood pressure; incidence of clinical hypertension; Blood pressure variability, Heart rate variability., Baseline,12 weeks,up to 24 weeks|Hemodynamics parameters, including pulse wave velocity(PWV), Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks|24-hours urine sodium and microalbumin, Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks|Carotid intima-media thickness(IMT,mm), Baseline,12 weeks,up to 24 weeks|Obesity parameters, including waist circumference (WC,cm) and body mass index(BMI, kg/m2), Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks|Insulin resistance assessed by fasting serum insulin and HOMA-IR, and control rate of diabetes., Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks
Sponsor/Collaborators: Sponsor: Third Affiliated Hospital of Third Military Medical University
Gender: ALL
Age: ADULT
Phases: PHASE4
Enrollment: 90
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2015-05
Completion Date: 2016-09
Results First Posted:
Last Update Posted: 2015-07-21
Locations:
URL: https://clinicaltrials.gov/show/NCT02503943